Update on vaccine-preventable diseases: Are adults in your community adequately protected?

Journal of Family Practice

Volumn 57, Issue 4, 2008, Pages

  Schaffner, William ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CAPSAICIN; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FAMCICLOVIR; GABAPENTIN; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIDOCAINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; OPIATE; PNEUMOCOCCUS VACCINE; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; VACCINE; VALACICLOVIR; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ANOREXIA; ANTIVIRAL THERAPY; BURNING SENSATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEART ARRHYTHMIA; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MORBIDITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PATIENT EDUCATION; PERIPHERAL EDEMA; PERTUSSIS; POSTHERPETIC NEURALGIA; PRIMARY HEALTH CARE; PROPHYLAXIS; PUBLIC HEALTH; RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STREPTOCOCCUS INFECTION; SYSTEMIC SIDE EFFECT; URINE RETENTION; VACCINATION; VERRUCA VULGARIS; VOMITING; WART VIRUS; XEROSTOMIA;

ADULT; ADVISORY COMMITTEES; AGED; FAMILY PRACTICE; HEPATITIS B; HEPATITIS B VACCINES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PHYSICIAN'S ROLE; UNITED STATES;

EID: 42149108538     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Poland GA, Schaffner W. Adult immunization guidelines: a patient safety and quality-of-care issue. Ann Intern Med. 2007;147:735-737.
2. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007-September 2008. Ann Intern Med. 2007;147:725-729.
3. Singleton JA. Vaccination coverage among adults. Presented at: National Vaccine Advisory Committee Session on Adult Immunization; October 27, 2007; Washington, DC.
4. Poland GA, Shefer AM, McCauley M, et al; National Vaccine Advisory Committee, Ad Hoc Working Group for the Development of Standards for Adult Immunization Practices. Standards for adult immunization practices. Am J Prev Med. 2003;25:144-150.
5. Centers for Disease Control and Prevention, National Foundation for Infectious Diseases. Results of CDCs National Immunization Survey [press conference]. Washington, DC; January 23, 2008.
6. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340.
7. Fiore AE, Shay DK, Haber P, et al; Advisory Committee on Immunization Practices. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1-60.
8. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.
9. Smith NM, Bresee JS, Shay DK, et al; Advisory Committee on Immunization Practices. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-42.
10. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322-1332.
11. Centers for Disease Control and Prevention (CDC). Updated recommendations from the Advisory Committee on Immunization Practices in response to delays in supply of influenza vaccine for the 2000-01 season. MMWR Morb Mortal Wkly Rep. 2000;49:888-892.
12. National Foundation for Infectious Diseases. Facts about pneumococcal disease. www.nfid.org/factsheets/pneumofacts.html. 2002. Accessed January 3, 2008.
13. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1-24.
14. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917-1924.
15. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747-1755.
16. Johnstone J, Marrie TJ, Eurich DT, et al. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007;167:1938-1943.
17. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605-1609.
18. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340-346.
19. Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Watson CP, Gershon AA, eds. Herpes Zoster and Postherpetic Neuralgia, 2nd Revised and Enlarged Edition. New York, NY: Elsevier Science Pub Co. 2001:39-64.
20. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748-753.
21. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996:67:241-251.
22. Ragozzino MW, Melton LJ 3rd, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61:310-316.
23. Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62:1545-1551.
24. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23:490-496.
25. Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356-363.
26. Rowbotham M, Harden N, Stacey B, et al; Gabapentin Postherpetic Neuralgia Study Group. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-1842.
27. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274-1283.
28. Pappagallo M, Haldey EJ. Pharmacological management of postherpetic neuralgia. CNS Drugs. 2003;17:771-780.
29. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837-1841.
30. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59:1015-1021.
31. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs. 2004;64:937-947.
32. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15:510-526.
33. Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-2284.
34. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55:1499-1507.
35. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10.
36. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
37. Giuliano AR, Nielson CM, Flores R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis. 2007;196:1146-1152.
38. Cox JT. Epidemiology and natural history of HPV. J Fam Pract. 2006;55(suppl):3-9.
39. Muñoz N, Castellsagué X, de González AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(suppl 3):S1-S10.
40. Tran N, Rose BR, O'Brien CJ. Role of human papillomavirus in the etiology of head and neck cancer. Head Neck. 2007;29:64-70.
41. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
42. Garland SM, Hernandez-Avila M, Wheeler CM, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943.
43. Luna J, Saah A, Hood S, et al; FUTURE III Investigators. Safety, efficacy, and immunogenicity of quadrivalent HPV vaccine (GARDASIL™) in women aged 24-25. Poster presented at: 24th International Papillomavirus Congress; November 3-9, 2007; Beijing, China. Poster PA1-04.
44. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed). 1988;296:612-614.
45. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004;23:985-989.
46. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child. 2003;88:802-806.
47. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J. 1998;17:412-418.
48. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55:1-37.
49. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555-1563.
50. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005;293:3003-3011.
51. Dehesa-Violante M, Nuñez-Nateras R. Epidemiology of hepatitis virus B and C. Arch Med Res. 2007;38:606-611.
52. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. Bio Drugs. 1998;10:137-158.
53. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
54. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.
55. Mast EE, Weinbaum CM, Fiore AE, et al; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55:1-33.
56. Centers for Disease Control and Prevention. Disease Burden from Hepatitis A, B, and C in the United States. www.cdc.gov/ncidod/diseases/hepatitis/ resource/PDFs/disease_burden.pdf. Accessed December 6, 2007.
57. Centers for Disease Control and Prevention. Hepatitis B vaccination coverage among adults - United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;55:509-511.
58. HHS-CDC NEWS: hepatitis B vaccination coverage among adults-United States, 2004. Ann Pharmacother. 2006;40:1230-1231.
59. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology. 2001;34:1225-1241.
60. Lee MS, Kim DH, Kim H, et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int J Epidemiol. 1998;27:316-319.
61. Goldstein ST, Zhou F, Hadler SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329-1339.
62. Michigan State Medical Society. Medicare Part D: What to look for in 2008. www.msms.org/AM/Template.cfm?Section=Home&TEMPLATE=/CM/ContentDisplay. cfm&CONTENTID=5394. Accessed January 16, 2008.
63. Medicare Learning Network. MLN Matters: Information for Medicare fee-for-service health care professionals. Important notice regarding vaccine administrations in 2008. MLN matters number SE0723.
64. Centers for Disease Control and Prevention. Vaccine Management: Recommendations for Storage and Handling of Selected Biologicals. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2007.
65. Postema AS, Breiman RF; National Vaccine Advisory Committee. Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation. MMWR Recomm Rep. 2000;49:1-13.
66. Centers for Disease Control and Prevention (CDC). Standards for adult immunization practices. www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/ H/standards-adult.pdf. Accessed February 22, 2008.
67. Jacobson VJ, Szilagyi P. Patient reminder and patient recall systems for improving immunization rates. Cochrane Database Syst Rev. 2005;CD003941.